Loading
A phase 3 trial of Nivolumab, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% is a phase 3 interventional study registered as NCT06561386 by Bristol-Myers Squibb, with 1000 participants planned, started 2024-10-07 and due to reach its primary completion in 2030-07-30. Interventions recorded: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Pembrolizumab.
Shares Pemetrexed, Bristol Myers Squibb, Nivolumab, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/